Isolation and use of solid tumor stem cells
A small percentage of cells within an established solid tumor have the properties of stem cells. These solid tumor stem cells give rise to both more tumor stem cells and to the majority of cells in the tumor that have lost the capacity for extensive proliferation and the ability to give rise to new tumors. Thus, solid tumor heterogeneity reflects the presence of tumor cell progeny arising from a solid tumor stem cell. We have developed a xenograft model in which we have been able to establish tumors from primary tumors via injection of tumors in the mammary gland of severely immunodeficient mice. These xenograft assay have allowed us to do biological and molecular assays to characterize clonogenic solid tumor stem cells. We have also developed evidence that strongly implicates the Notch pathway, especially Notch 4, as playing a central pathway in carcinogenesis.
1. A method for detecting gene expression in a single isolated solid tumor cell having a surface marker phenotype selected from the group consisting of:
(a) B38.1 + CD24 + ;
(b) B38.1 + LINEAGE − ;
(c) B38.1 + CD24 + LINEAGE − ;
(d) CD44 + CD24 + ;
(e) CD44 + CD24 + LINEAGE − ;
(f) B38.1 + CD24 − ;
(g) B38.1 + CD24 − LINEAGE − ;
(h) HER2 + B38.1 + CD24 − LINEAGE − ;
(i) EGFR − B38.1 + CD24 − LINEAGE − ;
(j) CD44 + CD24 −/lo ; and
(k) CD44 + CD24 −/lo LINEAGE − .
said method comprising:
(a) isolating the single solid tumor cell from a solid tumor of epithelial origin;
(b) amplifying a transcript produced by said cell; and
(c) detecting the presence of said amplified transcript
2. The method of claim 1 , wherein the transcript is amplified using RT-PCR.
3. The method of claim 1 , wherein more than one transcript is amplified.
4. The method of claim 1 , wherein the single isolated solid tumor cell is a breast solid tumor cell.
5. The method of claim 1 , wherein the single isolated solid tumor cell is a solid tumor stem cell.
6. The method of claim 5 , wherein the single isolated solid tumor stem cell has been exposed to a biological agent.
7. The method of claim 5 , which further comprises the step of:
(a) comparing a gene expression pattern of the single isolated solid tumor stem cell with a control; or
(b) comparing the presence of an amplified transcript of said isolated solid tumor stem cell with amplification of the transcript in a single isolated tumor cell from the solid tumor.
8. A method for detecting gene expression in a single isolated solid tumor stem cell having a surface marker phenotype selected from the group consisting of:
(a) B38.1 + CD24 + ;
(b) B38.1 + CD24 − ;
(c) CD44 + CD24 −/lo ;
(d) CD44 + CD24 −/lo LINEAGE;
(e) B38.1 + LINEAGE − ; and
(f) B38.1 + CD24 − LINEAGE − ;
said method comprising:
(a) isolating the single solid tumor stem cell from a solid tumor of epithelial origin;
(b) amplifying a transcript produced by said cell; and
(c) detecting the presence of said amplified transcript.
9. The method of claim 5 , wherein the solid tumor stem cell is a breast solid tumor stem cell.
10. The method of claim 8 , wherein the transcript is amplified using RT-PCR.
11. The method of claim 8 , wherein more than one transcript is amplified.
12. The method of claim 8 , wherein the single isolated solid tumor stem cell is a breast solid tumor stem cell.
13. The method of claim 8 , wherein the single isolated solid tumor stem cell has been exposed to a biological agent.
14. The method of claim 8 , which further comprises the step of:
(a) comparing a gene expression pattern of the single isolated solid tumor stem cell with a control; or
(b) comparing the presence of an amplified transcript of said isolated solid tumor stem cell with amplification of the transcript in a single isolated tumor cell from the solid tumor.
15. The method of claim 1 , wherein the single isolated solid tumor cell has been exposed to a biological agent.
16. The method of claim 1 , wherein the surface marker phenotype is CD44 + CD24 + .
17. The method of claim 4 , wherein the surface marker phenotype is CD44 + CD24 + .
18. The method of claim 8 , wherein the surface marker phenotype is CD44 + CD24 −/lo .
19. The method of claim 8 , wherein the surface marker phenotype is CD44 + CD24 −/lo LINEAGE − .
20. The method of claim 9 , wherein the surface marker phenotype is CD44 + CD24 −/lo .
21. The method of claim 9 , wherein the surface marker phenotype is CD44 + CD24 −/lo LINEAGE − .